Ari Geller, DO
Nephrology · Bloomfield, CTNPI 1710927892
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $185,183 of the $209,475 with a category attached, or 88.4%. 25 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 38.9% of the total. 2025 is the largest year on record at $82,944, 5.5 times the $15,194 reported in 2019. Among nephrology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 302 payments — averaging $693.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$81K
- Mallinckrodt Hospital Products Inc.$58K
- Akebia Therapeutics Inc$26K
- Lilly USA, LLC$25K
- Boehringer Ingelheim$12K
- Vifor Pharma, Inc.$5K
- plus $2K from 19 others
Across 188 payments — averaging $1683.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim International GmbH$136K
- Akebia Therapeutics Inc$84K
- AstraZeneca$59K
- GSK$23K
- Baxter Healthcare$10K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$5K
What the payments were for
- Consulting fees$6,9133%
- Speaking & faculty fees$185,18388%
- Travel & lodging$9,4365%
- Food & beverage$7,7884%
- Education$1550%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 91 | $81,398 |
| Mallinckrodt Hospital Products Inc. | 47 | $57,570 |
| Akebia Therapeutics Inc | 47 | $26,401 |
| Lilly USA, LLC | 26 | $25,458 |
| Boehringer Ingelheim | 19 | $11,585 |
| Vifor Pharma, Inc. | 12 | $5,069 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 12 | $246 |
| Travere Therapeutics, Inc. | 9 | $244 |
| Amgen(2 entities) | 6 | $241 |
| Medtronic | 3 | $229 |
| AstraZeneca(2 entities) | 5 | $213 |
| Baxter Healthcare | 3 | $152 |
| Aurinia Pharma U.S., Inc. | 3 | $135 |
| Veloxis Pharmaceuticals, Inc. | 1 | $114 |
| Novo Nordisk | 4 | $81 |
| Novartis | 2 | $62 |
| GSK | 2 | $57 |
| Ardelyx, Inc. | 2 | $43 |
| Fresenius USA Marketing, Inc. | 2 | $39 |
| Calliditas Therapeutics US Inc. | 1 | $29 |
| Bayer | 1 | $27 |
| Shire North American Group Inc | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Verona Pharma, Inc. | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JYNARQUE$79,856
- TERLIVAZ$57,235
- JARDIANCE$34,596
- Vafseo$25,668
- Veltassa$1,555
- SYMPLICITY G3$141
- Filspari$127
- Renal - Non Product Related$125
- Envarsus$114
- SOLIRIS$100
How this compares
$209,475 in reported general payments places this provider in the 95th percentile of 144 nephrology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 159 | $119,760 |
| FarxigaDapagliflozin Propanediol | 171 | $114,904 |
| KerendiaFinerenone | 49 | $51,444 |
| VeltassaPatiromer Calcium Sorbitex | 38 | $47,976 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 96 | $39,331 |
| AuryxiaFerric Citrate | 22 | $32,969 |
| Sevelamer Carbonate | 67 | $10,615 |
| ProsolParenteral Amino Acid 20% No.1 | 48 | $7,785 |
| DapagliflozinDapagliflozin Propanediol | 12 | $7,102 |
| Torsemide | 137 | $2,912 |
| Potassium Citrate ErPotassium Citrate | 38 | $2,299 |
| Calcium Acetate | 21 | $1,832 |
| Potassium Chloride | 32 | $1,632 |
| Calcitriol | 81 | $1,588 |
| Amlodipine Besylate | 171 | $1,015 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $11,585 | $119,760159 claims |
| AstraZenecaFarxiga | $213 | $114,904171 claims |
| BayerKerendia | $27 | $51,44449 claims |
| Akebia Therapeutics IncAuryxia | $26,401 | $32,96922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 nephrology providers in Connecticut.
Other nephrology in Bloomfield
- Sharad SathyanBloomfield$37K
- Robert AlpernNew Haven$4.9M
- Richard FormicaNew Haven$198K
- Stefan SomloNew Haven$111K
- James GavinTrumbull$103K
- Fredric FinkelsteinNew Haven$70K
- Justin BelcherNew Haven$59K
- David SimonOrange$59K
- Ladan GolestanehNew Haven$54K
- Jay GinsbergUncasville$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.